Data from Newron’s study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS)

Invitation to attend the General Meeting

Newron presents 2023 financial results and provides 2024 outlook

Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 financing agreement

Newron enters into an agreement for the subscription of up to 2.05 million newly issued shares

Newron reports exceptional one-year results of study 014/15 with evenamide in treatment-resistant schizophrenia (TRS)

Newron completes enrollment of schizophrenia patients in potentially pivotal study 008A with Evenamide

Newron TRS study 6 months’ results: Evenamide substantially improves patients to an extent that they no longer meet protocol entry criteria

Newron to present three posters on its clinical program evaluating evenamide in the treatment of schizophrenia at the 36th European College of Neuropsychopharmacology Congress

Newron appoints Margarita Chavez as board advisor

Pagination